| 07.24.23 | Trial failures pummel Gilead, Horizon, Bavarian, Kodiak; Pfizer drops sickle cell collab

Laden...

1 jaar geleden

Html
Tekst


A message from viralgen

Today's Big News

Jul 24, 2023

Gilead’s $4.9B CD47 bet faces latest setback as company cans MDS ambitions for magrolimab

Pfizer drops sickle cell disease collab with Syros inherited from GBT takeover

Roche signs onto Alnylam’s mid-stage hypertension med for $310 million upfront

Amgen’s lupus bets continue to flounder, even those on the Horizon

‘An unexpected outcome’: Bavarian Nordic crashes out of RSV race as vaccine fails phase 3 trial

‘Unexpected’ cataracts in phase 3 trials end Kodiak's hopes for eye drug, halving stock price

The Infinity-MEI merger saga finally ends in shareholders sinking the deal

Fierce Biotech Summit

October 16-18, 2023 | Boston, MA

This event is designed to bring together leaders and executives within the biotech and life sciences industry to discuss the most pressing challenges around product development, bringing an asset to market and building successful companies in this complex landscape.

Featured

Gilead’s $4.9B CD47 bet faces latest setback as company cans MDS ambitions for magrolimab

By James Waldron

Gilead’s $4.9 billion bet on Forty Seven has run into further trouble, with the Big Pharma pulling the plug on its myelodysplastic syndromes (MDS) ambitions for the lead CD47 asset from that deal in the face of a disappointing phase 3 trial.

11-14Sep

Join us: Digital Pharma EastPhiladelphia, PA

Pfizer drops sickle cell disease collab with Syros inherited from GBT takeover

By James Waldron

Pfizer is walking away from a sickle cell disease and beta thalassemia licensing deal with Syros Pharmaceuticals that it inherited from its takeover of Global Blood Therapeutics last year.

Roche signs onto Alnylam’s mid-stage hypertension med for $310 million upfront

By Max Bayer

Roche is betting more than $300 million in immediate cash that Alnylam's phase 2-stage hypertension med is a winner. Roche will have exclusive ex-US rights to the drug and both companies will co-commercialize and share profits inside the US.

Amgen’s lupus bets continue to flounder, even those on the Horizon

By Max Bayer

Amgen's difficult streak of lupus candidates persisted after Horizon's mid-stage asset failed a phase 2 trial. The newly-acquired company is continuing to study daxdilimab in other forms of the condition as well as alopecia.


A message from sino biological

‘An unexpected outcome’: Bavarian Nordic crashes out of RSV race as vaccine fails phase 3 trial

By James Waldron

Bavarian Nordic has crashed out of the respiratory syncytial virus vaccine race, with a phase 3 failure sending the company’s plans—and stock price—into a tailspin.

‘Unexpected’ cataracts in phase 3 trials end Kodiak's hopes for eye drug, halving stock price

By James Waldron

Kodiak Sciences has blamed an “unexpected increase in cataracts” as a reason for the failure of a pair of phase 3 trials that have led the biotech to drop its antibody biopolymer conjugate and halved its share price

The Infinity-MEI merger saga finally ends in shareholders sinking the deal

By James Waldron

Infinity Pharmaceuticals' merger saga has rumbled on almost as long as its namesake, but finally the biotech has closure—just not the way it wanted.

Pfizer, FDA work to ease shortage concerns as tornado relief efforts pick up at NC injectables plant

By Fraiser Kansteiner

Pfizer on Friday said it kicked off “immediate efforts” to provide relief and repair to the damage caused to its manufacturing facility in Rocky Mount, North Carolina. It noted crews are working around the clock to restore power, assess the structural integrity of the building and to relocate finished medicines to nearby sites for storage.

GSK’s Arexvy to lead new RSV vaccines sales race with Moderna a close second: report

By Ben Adams

We waited years for working RSV vaccines and in 2023, in the space of just a few weeks, we had two come all at once, with another on the horizon and a fresh approval for an RSV prevention med.

Galen Robotics nets FDA de novo clearance for ENT surgery helper

By Conor Hale

The motorized ES system helps stabilize the surgeon’s direct manual control of their instrument, with the goal of reducing natural hand tremors.

Respiratory patient groups see pharma’s reputation as boosted in 2022, but decry pricing, access to lung meds

By Ben Adams

Patient groups focused on lung diseases have observed an overall improvement in the pharmaceutical industry's reputation in 2022 compared to the previous year. Nevertheless, they continue to identify two major concerns for respiratory diseases—pricing and access to medicines—which remain unresolved.

Fierce Healthcare workforce tracker—Biofourmis lays off 48 U.S. employees; IntelyCare reduces workforce

By Heather Landi

The healthcare industry has felt the fallout from the economic downturn. Healthcare technology and digital health companies continue to cut jobs in the face of market uncertainty and the need to restructure operations. Here are the latest industry layoffs.

Fierce podcasts

Don't miss an episode

'The Top Line': Digital phenotyping, plus this week's headlines

This week on "The Top Line," we discuss the state of digital phenotyping, plus the vaccine patent lawsuits, the smallest insulin pump, and the rest of the week's headlines.

'Podnosis': Reprocessing medical devices, and incentive design

'The Top Line': New HIV therapies, plus this week's headlines


A message from Promab Biotechnologies

Resources

Whitepaper

Five ways to get the most from your lab and manufacturing facilities

Leading facilities practices and technologies can help improve the productivity of your research and manufacturing operations—and accelerate the journey from laboratory to saving lives.

Novel Antibodies for the Characterization of CAR-T Cells

Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more.

Improving the Patient Experience Through Research-Driven Design

Learn more about the current challenges and issues that eClinical technology providers are facing.

Develop a cost-effective cGMP chemical sourcing strategy

The right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes.

Sponsored by: Thermo Fisher Scientific Production Chemicals and Services

Whitepaper

Discovering High-Affinity, Functional Anti-GLP-1R Antibodies

Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties.

Medical Affairs Metamorphosis

This eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members.

Sponsored by: Blue Matter, strategic consultants in the life sciences

eBook

6 Tools Trial Sponsors Need to Take Action Earlier in Enrollment

Take a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions.